Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Ausztrália1. fázis

Sapu003 in Advanced mTOR-sensitive Solid Tumors

A legfontosabb adatok

Ki végzi
SAPU NANO (US) LLC
Hol
Adelaide (Ausztrália)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
1. fázis
Résztvevők
27 fő, tervezett
Kezdés
2025. dec. 15.
Várható befejezés
2026. dec.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • Sapu003
  • Exemestane 25 MG
A regiszteradat frissítve
2026. január 27.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat előrehaladott HR+/HER2-negatív emlőrákos, vesedaganatos, neuroendokrin daganatos, TSC-vel összefüggő daganatos vagy májrákos felnőtteket keres. A Sapu003 szert vizsgálja, exemesztánnal vagy anélkül.

Életkor
18 éves vagy idősebb.
Nem
Emlőrákos csoport: csak a menopauza utáni nők. A többi daganatcsoport: férfiak és nők.
A betegség stádiuma
Előrehaladott (áttétes vagy nem műthető) betegség. Az emlőrák HR+/HER2-negatív, IV. stádiumú vagy lokálisan előrehaladott legyen. A többi csoportban: vesesejtes karcinóma, neuroendokrin daganat, TSC-vel összefüggő daganat vagy hepatocelluláris karcinóma, mérhető betegséggel.
Korábbi kezelés
Emlőrákos csoport: a hormonkezelés nem vált be, ebbe beletartozik egy nem szteroid aromatázgátló, ha nem ellenjavallt. A többi csoport: a betegség legalább egy korábbi standard kezelés alatt tovább fejlődött, vagy nem tolerálták, kivéve ha nincs hatékony standard kezelés.
Biomarker vagy leletérték
Az emlőrákos csoportban HR-pozitív és HER2-negatív státusz. A többi csoportban nem kérnek ilyet.

A részvétel fő kizáró okai

  • Korábbi másik daganatos betegség, néhány kivétellel
  • Aktív agyi áttét
  • Ismert HIV-, hepatitis B- vagy hepatitis C-fertőzés
  • Terhes vagy szoptató nők
  • Más súlyos betegség vagy kezelést igénylő heveny fertőzés

A regiszter feltételei, szó szerint

Mind a 25 feltétel megnézéseKevesebb

Ki vehet részt

  • Sex and Age: Patients must be ≥ 18 years of age at the time of informed consent; Cohort A (HR+/HER2- breast cancer): Eligible patients must be postmenopausal women, defined as women ≥ 18 years of age with amenorrhea for ≥ 12 consecutive months without another pathophysiological cause; Cohort B (RCC, NETs, TSC-associated tumors, HCC): Eligible patients include both male and female adults with advanced disease
  • Cohort A HR+/HER2- Breast Cancer:; Eligible patients must meet all of the following:; Has histologically or cytologically documented advanced (metastatic or unresectable) hormone receptor-positive, HER2 negative breast cancer (advanced HR+ BC); Has stage IV or locally advanced breast cancer per the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, Seventh Edition; Has failed any combination endocrine therapy or relapse within 6 months of adjuvant chemotherapy for metastatic or locally advanced disease. Prior therapy should have included a non-steroidal aromatase inhibitor unless clinically contraindicated; Has agreed to participate in the study and signed the informed consent form prior to participation in any study activities
  • Cohort B Other Advanced mTOR-Sensitive Solid Tumors:; Eligible patients must meet all of the following:; Has histologically or cytologically confirmed advanced (metastatic or unresectable) disease in one of the following tumor types:; Renal Cell Carcinoma (RCC); Neuroendocrine Tumors (NETs); Tuberous Sclerosis Complex (TSC)-associated tumors; Hepatocellular Carcinoma (HCC); Has disease that is measurable and/or evaluable per RECIST v1.1 (or relevant criteria, if applicable); Has progressed on or is intolerant to at least one prior line of standard therapy appropriate for the specific tumor type, unless no effective standard therapy exists; Has agreed to participate in the study and signed the informed consent form prior to participation in any study activities
  • Patients must be on stable doses of metformin or statin
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Life expectancy ≥ 3 months
  • Hematology/chemistry: Patient has adequate hematological, renal, and hepatic function as defined by the following Screening laboratory values obtained within 7 days prior to randomization and assessed based on local labs (patients should not have received a transfusion within 7 days before the Screening laboratory assessments):; Absolute neutrophil count (ANC) ≥ 2,000 cells/mm3 (2 x109/L); Platelet count ≥ 100,000 cells/mm3 (100x109/L); Hemoglobin≥ 9 g/dL; Serum creatinine≤ 1.5 x the upper limit of normal (ULN); Total bilirubin ≤1.5 x ULN or direct bilirubin ≤1 x ULN for patients with total bilirubin levels > 1.5 ULN; AST (SGOT) / ALT (SGPT) ≤ 2.5 x ULN (≤5 x ULN for patients with metastases.); GFR ≥ 50 mL/min/1.73m2 by the CKD-EPI or MDRD formulas
  • All other clinical laboratory values deemed as normal or not clinically significant by the Principal Investigator/Sub-Investigator
  • Breastfeeding: Patients must be non-lactating. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding must be discontinued prior to the first dose of study drug
  • Female patients of reproductive potential to avoid becoming pregnant and to use effective contraception during the study and for 8 weeks after the last dose. Male patients with female partners of reproductive potential to use effective contraception during the study and for 4 weeks after the last dose
  • Able and willing to adhere to all protocol requirements and study procedures throughout the course of the study
  • Ability to comprehend and be informed of the nature of the study, as assessed by study clinic staff

Ki nem vehet részt

  • Patients who have not completely recovered from any toxicities from previous chemotherapy, hormone therapy, immunotherapy, target therapy, or radiotherapies ≥ Grade 1 per NCI CTCAE version 5.0, with the exception of alopecia
  • Patients who have received any of the following treatments within the specified timeframes prior to screening:; Prior chemotherapy within 30 days prior to screening (42 days for mitomycin C or nitrosoureas); Prior immunotherapy, prior anti-tumor hormonal therapy (for breast cancer patients), and prior radiotherapy within 30 days prior to screening; Radiotherapy is not allowed during study. Administration of other chemotherapy, immunotherapy, or anti-tumor hormonal therapy during the study is not allowed
  • Patients had major surgery within 30 days prior to randomization, or patients have not recovered from prior major surgery
  • Patients with active brain metastases. Patients with treated brain metastases are eligible provided they have no evidence of active brain disease and are off of definitive therapy (including steroids) at least 3 months prior to randomization
  • Known history or presence of:; Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C (serology to confirm absence is required within 7 days prior to randomization and assessed based on local labs); Alcohol abuse or dependence within one year prior to randomization; Drug abuse or dependence (marijuana, amphetamines, barbiturates, cocaine, opiates and benzodiazepines); Hypersensitivity or idiosyncratic reaction to everolimus, other rapamycin derivatives or its excipients; Severe allergic reactions (e.g., anaphylactic reactions, angioedema)
  • Patients may not participate in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or the use of investigational devices with therapeutic intent within 30 days prior to randomization and while enrolled in this study. Caution is recommended when administering Sapu003 and concomitantly with known substrates, PgP inhibitors, inhibitors, and inducers of the cytochrome P450 isoenzymes CYP2C8 and CYP3A4
  • Use of any strong inhibitors of cytochrome P450 (CYP) enzymes (e.g., fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (e.g., barbiturates (phenobarbital), carbamazepine, phenytoin and rifampin), in the previous 14 days before randomization until the last blood draw in the study
  • Acute active infection requiring antibiotics, antiviral agents, or antifungal agents within 14 days prior to randomization
  • Known history or presence of any clinically significant disease or condition other than cancer unless determined as not clinically significant by the Principal Investigator/Sub-Investigator. This includes, but is not limited to, the following: hepatic, renal/genitourinary, gastrointestinal (e.g., intra-abdominal inflammation), cardiovascular (e.g., congestive heart failure, ventricular arrhythmia, myocardial infarction, unstable angina pectoris), cerebrovascular, pulmonary (e.g., interstitial lung disease), endocrine, immunological, musculoskeletal, neurological, psychiatric, dermatological, or hematological (e.g., bleeding diathesis or coagulopathy)
  • History of difficulty with donating blood or difficulty in accessibility of central line
  • Patients with a history of other malignancies, except for adequately treated non-melanoma skin cancer, curatively treated in-situ carcinoma of the cervix, curatively treated in-situ carcinoma of the breast, or other solid tumors curatively treated with no evidence of disease for > 5 years
  • Sensory / Peripheral neuropathy of > Grade 1 per NCI CTCAE version 5.0 at Screening
  • Pregnant or lactating women

Helyszínek itt: Ausztrália

  • SOCRUAdelaide, AusztráliaContact: Sud AgarwalRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a phase 1b, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics of Sapu003 in combination with Exemestane in in patients with advanced mTOR-sensitive solid tumors (HR+/HER2-negative breast cancer, renal cell carcinoma [RCC], neuroendocrine tumors [NETs], tuberous sclerosis complex [TSC]-associated tumors, and hepatocellular carcinoma [HCC]).

A vizsgálat 2 csoportja

  • Cohort A - HR+/HER2- Breast CancerA vizsgált kezelés

    Cohort A (Combination Therapy - HR+/HER2- Breast Cancer): Post-menopausal women with advanced or metastatic hormone-receptor-positive, HER2-negative breast cancer receive Sapu003 (everolimus for injection) as a 30-min IV infusion once weekly at 5, 7.5 or 10 mg/m², together with oral exemestane 25 mg once daily, repeated in 28-day cycles.

    Kezelés: Sapu003 és Exemestane 25 MG

  • Cohort B - RCC / NET / TSC / HCCA vizsgált kezelés

    Cohort B (Monotherapy - RCC / NET / TSC / HCC): Adult patients with advanced renal cell carcinoma, neuro-endocrine tumours, tuberous-sclerosis-complex-associated tumours, or hepatocellular carcinoma receive Sapu003 (everolimus for injection) alone as a 30-min infusion once weekly at 5, 7.5 or 10 mg/m², repeated in 28-day cycles.

    Kezelés: Sapu003

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Sapu003 in Advanced mTOR-sensitive Solid Tumors (With or Without Exemestane)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 13.
A regiszteradat frissítve
2026. január 27.